MXPA04001848A - Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. - Google Patents

Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MXPA04001848A
MXPA04001848A MXPA04001848A MXPA04001848A MXPA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A MX PA04001848 A MXPA04001848 A MX PA04001848A
Authority
MX
Mexico
Prior art keywords
brain
composition
treating parkinson
receptor antagonist
dopaminergic neurotransmission
Prior art date
Application number
MXPA04001848A
Other languages
English (en)
Spanish (es)
Inventor
Benavides Jesus
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MXPA04001848A publication Critical patent/MXPA04001848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA04001848A 2001-08-29 2002-08-28 Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. MXPA04001848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111201A FR2829027A1 (fr) 2001-08-29 2001-08-29 Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
PCT/FR2002/002945 WO2003018060A1 (fr) 2001-08-29 2002-08-28 Composition pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau

Publications (1)

Publication Number Publication Date
MXPA04001848A true MXPA04001848A (es) 2004-06-15

Family

ID=8866793

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001848A MXPA04001848A (es) 2001-08-29 2002-08-28 Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson.

Country Status (9)

Country Link
US (1) US7105504B2 (enExample)
EP (1) EP1423146A1 (enExample)
JP (1) JP2005505539A (enExample)
AR (1) AR036303A1 (enExample)
CA (1) CA2458855A1 (enExample)
FR (1) FR2829027A1 (enExample)
IL (1) IL160558A0 (enExample)
MX (1) MXPA04001848A (enExample)
WO (1) WO2003018060A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
UA83230C2 (ru) 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
CN101636145B (zh) * 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
JP2010514832A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
SI2114933T1 (sl) 2007-01-04 2012-01-31 Prosidion Ltd Windrush Court Piperidinski gpcr-agonisti
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2005505539A (ja) 2005-02-24
WO2003018060A1 (fr) 2003-03-06
EP1423146A1 (fr) 2004-06-02
IL160558A0 (en) 2004-07-25
AR036303A1 (es) 2004-08-25
US7105504B2 (en) 2006-09-12
CA2458855A1 (en) 2003-03-06
FR2829027A1 (fr) 2003-03-07
US20050107356A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
MXPA04001645A (es) Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales.
MXPA04001848A (es) Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson.
AU2002337277A1 (en) Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
HUP0402026A3 (en) 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
BG64475B1 (bg) Ципразидонови соли
HUP0500107A3 (en) 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
IL157093A0 (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
MXPA05009103A (es) Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
NZ522326A (en) Adenosine A2A receptor antagonists
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
BG105256A (en) Muscarinic agonists and antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
SI1545537T1 (sl) Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
HUP0301228A3 (en) 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them
HUP0303737A3 (en) Indolinones, substituted in position 6, and their use as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
MXPA04005552A (es) Analogos de vitamina d.
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog